Axalta
Axalta's revenue fell 3.0% to $5.1 billion in fiscal 2025. Its operating margin was 14.4%, up from 13.4% a year earlier. Free cash flow was $453 million, up 3.9%. It paid out $165 million in dividends and buybacks, 36% of free cash flow. The diluted share count fell 1.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2016 to 2025, earnings per share grew 30.4% a year and net income 28.8% a year, as buybacks cut the share count by 11%.
Returns on capital
Cash flow
Payouts and share count
Valuation
Two ways to value Axalta yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Axalta's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Axalta's fiscal 2025 free cash flow of $453M, net cash of −$2.5B at December 31, 2025 and 217 million diluted shares, from its filings. The scenarios are fitted to Axalta: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 1.6% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 12%: 11% for a cyclical or higher-risk business (Specialty Chemicals), plus 1 point as a smaller company, worth $7.3B; the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $34.17
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
Value per share on three example scenarios, from Axalta's earnings per share of $1.71 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 20.5×, the middle of Axalta's own P/E today, its peers' median and its sector's median (the Materials median) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 13%, 12% and 11%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $34.17
- Value at this multiple, against the last close
- —
- Axalta's P/E at the last close
- 20.0×
| Company | Last close | Earnings per share | P/E today |
|---|---|---|---|
| Solstice Advanced MaterialsSOLS | $60.38 | $1.49 | 40.5× |
| AxaltaAXTA | $34.17 | $1.71 | 20.0× |
| H.B. FullerFUL | $49.13 | $3.59 | 13.7× |
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 841 | 645 | 700 | 593 | 657 |
| Debt incl. finance leases | 3,979 | 3,704 | 3,504 | 3,421 | 3,199 |
| Net debt (negative means net cash) | 3,139 | 3,059 | 2,804 | 2,828 | 2,542 |
| Net debt to EBITDA | 4.0x | 4.2x | 3.2x | 2.9x | 2.5x |
| Debt to equity | 2.7x | 2.5x | 2.0x | 1.8x | 1.4x |
| Interest coverage | 3.5x | 3.0x | 2.8x | 3.4x | 4.2x |
| Current ratio | 1.9x | 1.9x | 2.0x | 2.0x | 2.1x |
| Quick ratio | 1.4x | 1.4x | 1.5x | 1.5x | 1.5x |
Insider trades
No officer, director or 10% owner of Axalta reported buying or selling its shares on the open market between October 27, 2025 and October 26, 2026.
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | 9 of 9 | 8 of 9 | 7 of 9 |
| Accruals ratio | −4.3% | −2.5% | −3.6% |
Compare
Put Axalta side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Axalta | FY25 | −3.0% | 14.4% | 8.8% | 10.5% | 2.5x | 7 | |
| Albemarle | FY25 | −4.4% | −7.1% | 13.5% | −2.4% | 5.8x | 7 | Compare |
| Huntsman | FY25 | −5.8% | −2.3% | 2.0% | −2.2% | 10.1x | 2 | Compare |
| Solstice Advanced Materials | FY25 | 3.1% | — | 3.1% | 12.2% | 2.3x | — | Compare |
| H.B. Fuller | FY25 | −2.7% | — | 3.5% | 6.3% | 3.6x | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 4,093 | 4,377 | 4,696 | 4,482 | 3,738 | 4,416 | 4,884 | 5,184 | 5,276 | 5,117 |
| Revenue growth | −0.4% | 7.0% | 7.3% | −4.5% | −16.6% | 18.2% | 10.6% | 6.1% | 1.8% | −3.0% |
| Gross profit | 1,564 | 1,596 | 1,590 | 1,564 | 1,280 | 1,429 | 1,418 | 1,618 | 1,798 | 1,762 |
| Research and development | 58 | 65 | 73 | 70 | 55 | 62 | 66 | 74 | 74 | 71 |
| Operating income | 405 | 364 | 442 | 488 | 306 | 462 | 423 | 588 | 706 | 735 |
| Net income | 39 | 37 | 207 | 249 | 122 | 264 | 192 | 267 | 391 | 378 |
| Diluted EPS (US$) | 0.16 | 0.15 | 0.85 | 1.06 | 0.52 | 1.14 | 0.86 | 1.21 | 1.78 | 1.74 |
| Diluted shares (millions) | 244 | 246 | 243 | 236 | 236 | 232 | 222 | 222 | 220 | 217 |
| Cash flow | ||||||||||
| Cash from operations | 559 | 540 | 496 | 573 | 509 | 559 | 294 | 575 | 576 | 649 |
| Capital expenditure | 136 | 125 | 143 | 112 | 82 | 122 | 151 | 138 | 140 | 196 |
| Free cash flow | 423 | 415 | 353 | 461 | 427 | 437 | 143 | 437 | 436 | 453 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 58 | 254 | 105 | 26 | 244 | 200 | 50 | 100 | 165 |
| Acquisitions | 115 | 564 | 83 | 3 | 1 | 649 | 3 | 106 | 301 | 48 |
| Stock-based compensation | 41 | 38 | 37 | 16 | 15 | 15 | 22 | 26 | 28 | 25 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 535 | 770 | 694 | 1,018 | 1,361 | 841 | 645 | 700 | 593 | 657 |
| Debt incl. finance leases | 3,312 | 3,962 | 3,912 | 3,960 | 3,893 | 3,979 | 3,704 | 3,504 | 3,421 | 3,199 |
| Total assets | 5,866 | 6,832 | 6,676 | 6,818 | 7,157 | 7,217 | 7,059 | 7,272 | 7,249 | 7,599 |
| Total liabilities | 4,620 | 5,424 | 5,365 | 5,408 | 5,677 | 5,678 | 5,560 | 5,499 | 5,293 | 5,206 |
| Shareholders' equity | 1,125 | 1,276 | 1,205 | 1,354 | 1,433 | 1,493 | 1,454 | 1,727 | 1,912 | 2,346 |
| Margins and ratios | ||||||||||
| Gross margin | 38.2% | 36.5% | 33.9% | 34.9% | 34.2% | 32.4% | 29.0% | 31.2% | 34.1% | 34.4% |
| Operating margin | 9.9% | 8.3% | 9.4% | 10.9% | 8.2% | 10.5% | 8.7% | 11.3% | 13.4% | 14.4% |
| Net margin | 0.9% | 0.8% | 4.4% | 5.6% | 3.2% | 6.0% | 3.9% | 5.2% | 7.4% | 7.4% |
| Free cash flow margin | 10.3% | 9.5% | 7.5% | 10.3% | 11.4% | 9.9% | 2.9% | 8.4% | 8.3% | 8.8% |
| Return on capital | 5.4% | 4.2% | 7.7% | 8.4% | 7.3% | 8.3% | 6.8% | 9.8% | 11.9% | 10.5% |
| Return on equity | 3.5% | 3.1% | 16.7% | 19.5% | 8.7% | 18.0% | 13.0% | 16.8% | 21.5% | 17.8% |
| Return on assets | 0.7% | 0.6% | 3.1% | 3.7% | 1.7% | 3.7% | 2.7% | 3.7% | 5.4% | 5.1% |
| Net debt to EBITDA | 3.8x | 4.5x | 4.0x | 3.5x | 4.0x | 4.0x | 4.2x | 3.2x | 2.9x | 2.5x |